Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na(+)/H(+) exchanger-1 or lower [Na(+)](i) in the heart

AIMS : Emipagliflozin (EMPA) is a potent inhibitor of the renal sodium-glucose co-transporter 2 (SGLT2) and an effective treatment for type-2 diabetes. In patients with diabetes and heart failure, EMPA has cardioprotective effects independent of improved glycaemic control, despite SGLT2 not being ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Yu Jin, Park, Kyung Chan, Tokar, Sergiy, Eykyn, Thomas R, Fuller, William, Pavlovic, Davor, Swietach, Pawel, Shattock, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683707/
https://www.ncbi.nlm.nih.gov/pubmed/33135077
http://dx.doi.org/10.1093/cvr/cvaa323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683707/
https://www.ncbi.nlm.nih.gov/pubmed/33135077
http://dx.doi.org/10.1093/cvr/cvaa323

Ejemplares similares